Preoperative midazolam

ApprovedSmall molecule

MMedical University of South Carolina

Preoperative midazolam is one of 3 small molecule programs targeting Anesthesia Induction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anesthesia InductionRecruiting

Anesthesia InductionApproved

Recruiting

Competition

Competitive Landscape

2 competitors in Anesthesia Induction

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Approved

1 2

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Approved

2 3

Preoperative midazolam

MMedical University of South Carolina

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Anesthesia Induction

NCT06144177

Clinical

Trials by Indication[1]

Anesthesia Induction1 trial

Induction in the Dark: a Prospective Randomized Control Trial for Perioperative Pediatric Anxiety

Recruiting·MMedical University of South Carolina·Approved·NCT06144177·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Preoperative midazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Preoperative midazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Preoperative midazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedical University of South Carolina

Preoperative midazolam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Anesthesia Induction1 trial

References

Drug Info

Quick Facts

Related News